Eisai acquires rights to Teikoku's antiulcerant

28 August 2000

Eisai says it has acquired exclusive rights to conduct clinical trialsand market worldwide Teikoku Chemical's TKS1044, which the latter says is effective against Helicobacter pylori, the bacteria associated with gastric ulcers. The compound is currently in the preclinical stage of development.

Eisai is also hopeful that TKS1044 could be used as a stand-alone therapy to eliminate the bacterium, as opposed to current therapy which requires a combined antiulcerant and antibiotic approach, a company spokesperson said. Whether it can be used alone will be determined in human trials, it was noted, and Eisai has not commented about when these will be initiated.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight